News

News 2017-11-19T23:06:00+00:00

Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

LONDON, PARIS 21 FEBRUARY 2018: Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies. Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance [...]

February 21st, 2018|

Arix Bioscience and Fosun International sign strategic agreement to develop and commercialise new clinical therapies for patients

LONDON, HONG KONG  19 FEBRUARY 2018: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company building and financing innovative young medical businesses and Fosun International Limited (00656:HK) (“Fosun”), jointly announce a strategic agreement to develop and commercialise new clinical therapies for patients. As part of the agreement, Arix and Fosun will collaborate to invest in and create new [...]

February 19th, 2018|

CEO Letter to Shareholders

LONDON, 4 January 2018:  As 2018 gets underway, I would like to reflect on Arix Bioscience plc’s (LSE: ARIX) (“Arix Bioscience” or “Arix”) first year as a public company and offer some thoughts on the year ahead.  We started 2017 with the ambition of building a business with the capital, the skills and the experience to take breakthroughs in life sciences and accelerate their development [...]

January 4th, 2018|

Publication of Pre-clinical data of a dual targeting CAR for treatment of Multiple Myeloma

- APRIL CAR-T cells concurrently target BCMA and TACI to reduce the risk of antigen negative disease relapse - London, 2 January 2018 – Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of pre-clinical data from a novel, dual-targeted, proliferating-inducing ligand (APRIL) Chimeric Antigen Receptor (CAR) in Blood, the journal of the [...]

January 2nd, 2018|

Arix Bioscience co-leads $30 million financing for Aura Biosciences

Funding to advance development of Aura’s novel treatment to selectively destroy cancer cells; lead candidate AU-011 currently in Phase 1b/2 study to treat ocular melanoma, an orphan indication LONDON, 21 December 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience”), a global healthcare and life science company supporting medical innovation, today announces that it has co-led a $30 million Series C financing round for Aura Biosciences [...]

December 21st, 2017|

Arix Bioscience leads $30 million financing for Atox Bio

Funding to advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio’s on-going Phase 3 clinical development in necrotising soft tissue infections  Arix achieves target of 12 Group Businesses by the end of 2017, successfully building a balanced group with multiple, potentially significant milestones over the next 12 months  LONDON, 4 December 2017: Arix Bioscience plc (LSE: ARIX) (“Arix [...]

December 4th, 2017|

Autolus announces publication in Nature

London, 14 November 2017 – Autolus Limited, a clinical-stage biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies, today announced the publication of an article in Nature Medicine describing a unique targeting strategy for the treatment of patients with T-cell lymphomas.

November 14th, 2017|

Sir John Banham retires from Board of Directors of Arix Bioscience plc

LONDON, 10 November 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Sir John Banham is retiring from his position as a Non-Executive Director of Arix Bioscience. Sir John, who is 76, has been Chairman of the Audit and Risk Committee, and has helped to oversee the Company’s growth both [...]

November 10th, 2017|

Arix Bioscience to present at two investor conferences in November

LONDON, 1 November 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience") a global healthcare and life science company supporting medical innovation, will present at two investor conferences in November: Stifel 2017 Healthcare Conference on November 15, 2017 at 11:40 a.m. ET at the Lotte New York Palace Hotel. Jonathan Peacock, Chairman, will make the presentation, and will participate in one-on-one investor meetings at the conference on [...]

November 1st, 2017|

Arix Bioscience appoints Giles Kerr to Board of Directors

LONDON, 17 October 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces the appointment of Giles Kerr as a Non-Executive Director of the Company and chairman of the Board’s Audit Committee. The appointment is with immediate effect. Giles Kerr has 36 years’ experience in finance across a broad range of industrial [...]

October 17th, 2017|